Continuous Glucose Monitoring: A Revolution Powered by DexCom

Small company DexCom, finds itself a leader in continuous glucose monitoring, the hottest new segment of glucose monitoring, a business otherwise dominated by giant companies. Continuous glucose monitoring (CGM) is all the buzz at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in the home (or the hospital) glucose readings at any hour of the day without the need to get out the finger-stick testing paraphernalia. More than that, though, CGM is a new tool for achieving tight glycemic control, and avoiding the excursions above and below the normal glucose levels, which are responsible for the hospitalizations as well as the long-term harmful consequences of diabetes. As a frontrunner in the field, DexCom shares with Medtronic the challenge of proving the value of CGM to payers, especially since the task involves throwing over the gold standard by which successful glycemic control is measured-the HbA1c test.

John Lennon said that life is what happens when you’re busy making other plans. For DexCom Inc., that’s not a bad thing. Founded in 1999, DexCom tried, but failed, to develop a fully implantable glucose sensor that would last for at least a year and help patients with diabetes avoid the numerous daily finger-sticks required to measure their blood glucose. Along the way, however, it did succeed in gaining FDA approval for a sensor that enables continuous glucose monitoring (CGM) for seven days at a time, and that may be enough to revolutionize diabetes care.

CGM is a hot topic at diabetes and critical care clinical meetings these days. CGM systems give diabetic patients in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Novo Nordisk Foundation Brings World’s Most Powerful Computer To Nordics

 
• By 

Denmark’s €80m QuNorth project, co-led by the Novo Nordisk Foundation, launches most powerful quantum computer to advance drug discovery and broader scientific research across the Nordics.

Rising Leaders 2025: Daniel Cohen’s Transition From Grad To AI Pioneer In Drug Discovery

 
• By 

A 25-year-old's “naive optimism” becomes the driving force behind one of biopharma's most ambitious AI ventures.

How Blood-Based Biomarkers Are Transforming Alzheimer’s Clinical Research And Patient Care

 
• By 

Blood-based biomarkers are revolutionizing Alzheimer’s diagnosis by enabling earlier, more accessible, and less invasive detection, which is accelerating clinical research and improving patient care outcomes.

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By 

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

More from In Vivo

Enabling Precision Medicine At Scale Through Digital Innovation And AI

 
• By 

AI is reshaping clinical trials by enabling precision medicine, accelerating patient stratification, optimizing trial design, and transforming complex data into actionable insights for faster, more effective drug development.

J&J Challenges Medtronic At The Top Of Medtech Rankings

 
• By 

Medtronic held its grip on first place in the 2024 global medical device and diagnostics rankings after losing it two years ago to Abbott, which is now in third place behind fast-rising, acquisitive Johnson & Johnson MedTech.

‘By Most Measures A Failure’: Ten Years On From Teva-Actavis

 
• By 

A decade after Teva’s $40.5bn acquisition of Actavis Generics, the deal remains a defining moment for the company. This retrospective explores Teva’s hopes, consequences, leadership shifts, and the firm’s new growth strategy under CEO Richard Francis.